Back to trial
Eligibility Pre-Screening
A phase II, 12 month, randomized, sham-controlled trial of ranibizumab (Lucentis) combined with grid laser compared with laser alone for the treatment of recalcitrant, diabetic macular oedema.
This is a simplified pre-screening tool. Your answers help estimate whether you might qualify, but only the research team can confirm your eligibility. This is not medical advice.
Question 1 of 70%